Donald Trump credited for his swift coronavirus recovery won’t become widely available because it’s impossible to make enough for everyone who might need it, according to the Swiss pharmaceutical giant working on scaling up production.“We’ll never be able to produce enough," said Bill Anderson, drugs chief at Roche Holding AG, which is working together with US biotech Regeneron Pharmaceuticals Inc.
on the project. “This is clearly part of the answer for the world, not the answer. Hopefully we’ll have vaccines and other therapeutics."The partners will probably be able to make as many as 2 million doses per year by the end of next March if the drug cocktail wins regulatory approval, Anderson said.